Analysts Set Intuitive Surgical, Inc. (NASDAQ:ISRG) Price Target at $583.83

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) have earned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $613.10.

Several research firms recently weighed in on ISRG. Leerink Partners lifted their price target on Intuitive Surgical from $490.00 to $548.00 in a report on Monday, January 27th. Evercore ISI upped their price objective on Intuitive Surgical from $490.00 to $530.00 in a research report on Monday, January 27th. Oppenheimer reiterated a “market perform” rating on shares of Intuitive Surgical in a report on Friday, October 18th. Piper Sandler reiterated an “overweight” rating and set a $670.00 target price (up from $538.00) on shares of Intuitive Surgical in a research report on Friday, January 24th. Finally, Erste Group Bank raised Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 19th.

Insiders Place Their Bets

In other Intuitive Surgical news, insider Jamie Samath sold 22,903 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $525.00, for a total value of $12,024,075.00. Following the completion of the sale, the insider now owns 8,757 shares in the company, valued at approximately $4,597,425. This trade represents a 72.34 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Amal M. Johnson sold 4,635 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the transaction, the director now owns 12,275 shares of the company’s stock, valued at $6,955,015. This trade represents a 27.41 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,843 shares of company stock worth $15,357,560. Insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Berbice Capital Management LLC bought a new position in Intuitive Surgical in the 4th quarter worth about $26,000. Godsey & Gibb Inc. raised its position in Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares during the period. MidAtlantic Capital Management Inc. purchased a new stake in Intuitive Surgical during the 3rd quarter valued at about $33,000. Decker Retirement Planning Inc. purchased a new position in shares of Intuitive Surgical in the fourth quarter worth $36,000. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Intuitive Surgical during the third quarter worth about $38,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Price Performance

ISRG stock opened at $571.88 on Monday. The stock has a market cap of $203.69 billion, a price-to-earnings ratio of 89.22, a price-to-earnings-growth ratio of 5.52 and a beta of 1.39. Intuitive Surgical has a one year low of $364.17 and a one year high of $616.00. The company has a fifty day moving average price of $549.92 and a two-hundred day moving average price of $508.00.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.